Protara Therapeutics, Inc. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
Protara Therapeutics, Inc. (TARA) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $1.09 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-11
- Protara Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $1.09M, a 48.10% increase year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $1.04M, a 46.77% increase year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $851.00K, a 3.53% increase year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $736.00K, a 22.77% decline year-over-year.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $3.14M, a 13.83% decline from fiscal 2024.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $3.65M, a 25.37% decline from fiscal 2023.
- Protara Therapeutics, Inc. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $4.88M.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.09M 10-Q · filed 2026-08-11 | $2.13M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $1.04M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $3.14M 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $851.00K 10-Q · filed 2025-11-10 | $1.59M derived: sum of 2 quarters · filed 2026-08-11 | $2.30M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $736.00K 10-Q · filed 2026-08-11 | $1.45M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $712.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $3.65M 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $822.00K 10-Q · filed 2025-11-10 | $1.77M derived: sum of 2 quarters · filed 2025-11-10 | $2.85M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $953.00K 10-Q · filed 2025-11-10 | $2.03M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $1.07M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $4.88M 10-K · filed 2025-03-05 | |||
| 2023-09-30 | $1.17M 10-Q · filed 2024-11-12 | $2.46M derived: sum of 2 quarters · filed 2024-11-12 | $3.73M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.29M 10-Q · filed 2024-11-12 | $2.55M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $1.26M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |